HIF-1 α N-terminal activation domain (530-698) human
SIGMA/SRP2099 - recombinant, expressed in E. coli, ≥80% (SDS-PAGE)
Synonym: HIF-1alpha; HIF1; HIF1-alpha; MOP1; PASD8; bHLHe78
Product Type: Chemical
Immunoblotting HIF-1 α N-terminal activation domain (530-698) Cat. No. SRP2099: HIF-1 α N-terminal activation domain (530-698) was separated on SDS-PAGE using 1-3 μg protein (left); and a protein marker (right).
| assay | ≥80% (SDS-PAGE) |
| biological source | human |
| color | colorless to clear |
| concentration | 800 μg/mL |
| form | frozen liquid |
| mol wt | ~19.8 kDa |
| NCBI accession no. | NM_001530   |
| packaging | pkg of 10 μg |
| recombinant | expressed in E. coli |
| shipped in | dry ice |
| storage condition | avoid repeated freeze/thaw cycles |
| storage temp. | −70°C |
| UniProt accession no. | Q16665 |
| Biochem/physiol Actions: | Hypoxia-inducible factor-1 (HIF1) is a transcription factor found in mammalian cells cultured under reduced oxygen tension that plays an essential role in cellular and systemic homeostatic responses to hypoxia. HIF1 is a heterodimer composed of an alpha subunit and a beta subunit. The beta subunit has been identified as the aryl hydrocarbon receptor nuclear translocator (ARNT). This gene encodes the alpha subunit of HIF-1. HIF-1α contains two transactivation domains located between amino acids 531 and 826. Overexpression of a natural antisense transcript (aHIF) of this gene has been shown to be associated with nonpapillary renal carcinomas. Two alternative transcripts encoding different isoforms have been identified. Specific disruption of the HIF-1 pathway is important for exploring its role in tumor biology and developing more efficient weapons to treat cancer. HIF-1alpha is a master regulator of the hypoxic response, and its proangiogenic activities include, but are not limited to, regulation of vascular endothelial growth factor (VEGF). HIF-1alpha protein expression often seen in invasive breast cancer. Recent data demonstrates that HIF-1alpha knockdown reduces tumorigenicity of MCF-7 cells and suggest a promising combination of both anti-HIF-1 strategy and traditional chemotherapy to improve cancer treatment. |
| Physical form: | Clear and colorless frozen liquid solution |
| Preparation Note: | Use a manual defrost freezer and avoid repeated freeze-thaw cycles. While working, please keep sample on ice. |
| RIDADR | NONH for all modes of transport |
| WGK Germany | WGK 1 |
| Flash Point(F) | Not applicable |
| Flash Point(C) | Not applicable |
| Purity | ≥80% (SDS-PAGE) |
| Storage Temp. | −70°C |
| UNSPSC | 12352200 |